Therapeutic options in the management of metastatic breast cancer

ONCOLOGY

Volumn 22, Issue 6, 2008, Pages 614-623

  Higgins, Michaela J ^a   Wolff, Antonio C ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AXITINIB; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CONTRAST MEDIUM; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUORODEOXYGLUCOSE; FLUOROURACIL; GEMCITABINE; HORMONE; IRINOTECAN; IXABEPILONE; LAPATINIB; METHOTREXATE; NAVELBINE; PACLITAXEL; PERTUZUMAB; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BRAIN ISCHEMIA; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CARDIOTOXICITY; CAUSE OF DEATH; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIAGNOSTIC PROCEDURE; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; FATIGUE; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; METASTASIS; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN EXPRESSION; PROTEINURIA; QUALITY OF LIFE; REVIEW; SENSORY NEUROPATHY; STOMATITIS; SURGICAL APPROACH; THROMBOCYTOPENIA; UNITED STATES; BREAST TUMOR; DRUG EFFECT; FEMALE; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 49149112250     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007.
2. Khatcheressian JL, Wolff AC, Smith TJ, et al: American Society of Clinical Oncology 2006 update of the breast cancer follow up and management guidelines in die adjuvant setting. J Clin Oncol 24:5091-5097, 2006.
3. Pecking AP, Mechelany-Corone C, Bertrand-Kermorgant F, et al: Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography. Clin Breast Cancer 2:229-234, 2001.
4. Cook GJ, Houston S, Rubens R, et al: Detection of bone metastases; in breast cancer by 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16:3375-3379, 1998.
5. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312, 2007.
6. Gorla SR, Steel J, Cohn R, et al: Impact of surgical resection of primary breast tumor in stage IV breast cancer on local contraol and survival (abstract 629). J Clin Oncol 23(16S):35s, 2005.
7. Holmes FA, Buzdar AU, Kau SW, et al: Combined-modality approach for patients with isolated recurrences of breast cancer (IV-NED): The M.D. Anderson experience. Breast Dis 7:7-20, 1994.
8. Albain K, Green S, Ravdin P, et al: Overall survival after cyclophosphamide, adriamycin, 5-FU, and tamoxifen is superior to T alone in postmenopausal, receptor (+), node (+) breast cancer: New findings from phase III southwest oncology group intergroup trial S8814 (abstract 94). Proc Am Soc Clin Oncol 20:24a, 2001.
9. Mauri D, Pavlidis N, Polyzos NP, et al: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: Meta-analysis. J Natl Cancer Inst 98:1285-1291, 2006.
10. Rose C, Vtoraya O, Pluzanska A, et al: An open randomised trial of second-line endocrine therapy in advanced breast cancer. companson of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39:2318-2327, 2003.
11. Robertson JF, Osborne CK, Howell A, et al: Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer 98:229-238, 2003.
12. Ingle JN, Suman VJ, Rowland KM, et al: Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 24:1052-1056, 2006.
13. Ylijn JGM, Blamey RW, Boccardo F, et al: Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 19:343-353, 2001.
14. Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression and survival in metastatic breast cancer. N Engl J Med 351:781-791, 2004.
15. Cristofanilli M, Hayes DF, Budd GT, et al: Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23:1420-1430, 2005.
16. Carrick S, Parker S, Wilcken N, et al: Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev (2):CD003372, 2005.
17. Smalley RV, Carpenter J, Bartolucci A, et al: A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: A Southeastern Cancer Study Group project. Cancer 40:625-632, 1977.
18. A'Hern RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67:801-805, 1993.
19. Findlay BP, Walker-Dilks C: Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 2:140-146, 1998.
20. Harris L, Batist G, Belt R, et al: Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94:25-36, 2002.
21. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-717, 2005.
22. Pacilio C, Morabito A, Nuzzo F, et al: Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. Br J Cancer 94:1233-1236, 2006.
23. Chan S, Fredrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 17:2341-2354, 1999.
24. Jones SE, Erban J, Overmoyer B, et al: Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542-5551, 2005.
25. Seidman AD, Berry D, Cirrincione C, et al: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642-1649, 2008.
26. Sparano JA, Wang M, Martino S, et al: Weekly paclitaxel in the adjuvant treatment of breast cancer N Eng J Med 358:1663-1671, 2008.
27. Gradishar WJ, Tjulandin S, Davidson N, et al: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794-803, 2005.
28. Gradishar W, Krasnojon D, Cheporov S, et al: Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC) (abstract 1032). J Clin Oncol 25(18S):40s, 2007.
29. Piccart MJ, Burzykowski T, Sledge G, et al: Effects of taxanes alone or in combination with anthracyclines on tumor response, progression-free survival and overall survival in first-line chemotherapy of patients with metastatic breast cancer: An analysis of 4,256 patients randomized in 12 trials (abstract 6086). Breast Cancer Res Treat 94(suppl 1): 278, 2005.
30. Blum JL, Dieras V, Lo Russo PM, et al: Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759-1768, 2001.
31. Sledge G, Miller C, Moisa C, et al: Safety and efficacy of capecitabine plus bevacizumab as fist-line in metastatic breast cancer (abstract 1013). J Clin Oncol 25(18S):35s, 2007
32. O'Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20:2812-2823, 2002.
33. O'Shaughnessy J: Gemcitabine combination chemotherapy in metastatic breast cancer: Phase II experience. Oncology (Williston Park) 17(12 suppl 14):15-21, 2003.
34. Seidman AD: Gemcitabine as single-agent therapy in the management of advanced breast cancer. Oncology (Williston Park) 15(2 suppl 3):11-14, 2001.
35. Albain KS, Nag S,Calderillo-Ruiz G, et al: Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival (abstract 510). Proc Am Soc Clin Oncol 23:5, 2004.
36. Canobbio L, Boccardo F, Pastorino G, et al: Phase II study of navelbine in advanced breast cancer. Semin Oncol 16(2 suppl 4):33-36, 1989.
37. Degardin M, Bonneterre J, Hecquet B, et al: Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 5:423-426, 1994.
38. Roche H, Cure, Bunnell et al A phase II study of epothilone analog BMS-247550 in patients (pts) with metastatic breast cancer (MBC) previously treated with an anthracycline (abstract 69). Proc Am Soc Clin Oncol 22:18, 2003.
39. Low JA, Wedam SB, Brufsky A, et al: A phase 2 trial of BMS-247550 (ixabepilone), an epothilone B analog, given daily x 5 in breast cancer (abstract 545). Proc Am Soc Clin Oncol 23:13, 2004.
40. Thomas ES, Gomez HL, Li RK, et al: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210-5217, 2007.
41. Miller K, Wang M, Gralow J, et al: Paelitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007.
42. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999.
43. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002.
44. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001.
45. Esteva FJ, Valero V, Booser D, et al: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800-1808, 2002.
46. Burstein HJ, Kuter I, Campos SM, et al: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19:2722-2730, 2001.
47. Burstein HJ, Keshaviah A, Baron AD, et al: Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study. Cancer 110:965-972, 2007.
48. von Minckwitz G, Vogel P, Schmidt M, et al: Trastuzumab treatment beyond progression in patients with HER-2 positive metastatic breast cancer the TBP study (GBG 26/BIG 305) (abstract 4056). Breast Cancer Res Treat 106(suppl 1), 2007.
49. Mackey JR, Kaufman B, Clemens M, et al: Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer (abstract 3). Breast Cancer Res Treat 100(suppl 1), 2006.
50. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006.
51. Geyer CE, Martin A, Newstat B, et al: Lapatinib plus capecitabine in HER2+ advanced breast cancer; genomic and updated efficacy data (abstract 1035). J Clin Oncol 25(18S):40s, 2007.
52. Lin NU, Paul D, Dieras V, et al: Lapatinib and capecitabine for the treatment of brain metastases in patients with HER2+ breast cancer - an updated analysis from EGF105084 (abstract 1035). Breast Cancer Res Treat 106(suppl 1), 2007.
53. Di Leo A, Gomez H, Aziz Z, et al: Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III randomized, double-blind study of 580 patients (abstract 1011). J Clin Oncol 25(18S):34s, 2007.
54. Baselga J, Cameron D, Miles D, et al: Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T (abstract 1004). J Clin Oncol 25(18S):33s, 2007.
55. Beeram M, Krop I, Modi S, et al: A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC) (abstract 1042). J Clin Oncol 25(18S):42s, 2007.
56. Carey LA, Mayer E, Marcom PK, et al: TBCRC 001: EGFR inhibition with cetuximab in metastatic triple negative (basal-like) breast cancer (abstract 307). Breast Cancer Res Treat 106(suppl 1), 2007.
57. O'Shaughnessy J, Weckstein DJ, Vukelja SJ, et al: Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer (abstract 308). Breast Cancer Res Treat 106(suppl 1), 2007.
58. Burstein HJ, Elias AD, Rugo, HS, et al: Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810-1816, 2008.
59. Costanza ME, Weiss RB, Henderson IC, et al: Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study - Cancer and Leukemia Group B 8642. J Clin Oncol 17:1397-406, 1999.
60. Pavlakis N, Schmidt R, Stockler M: Bisphosphonates for breast cancer. Cochrane Database Syst Rev (3):CDO03474, 2005.
61. Ross JR, Saunders Y, Edmonds PM, et al: Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 327:469,2003.
62. Khosla S, Burr D, Cauley J, et al: Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479-1491, 2007.
63. Hillner BE, Ingle JN, Chlebowski RT, et al: 2003 Update on the role of bisphosphonates; and bone health issues in women with breast cancer. J Clin Oncol 21;4042-4037, 2003.
64. Crawford J: Erythropoietin: High profile, high scrutiny. J Clin Oncol 25:1021-1023, 2007.